IP Library Granted Patent US 12,117,397
Granted Patent B2
US 12,117,397 · App. 17/818,637 · Granted Oct 15, 2024

Biochip device

Inventors: Claude Weisbuch (Paris, FR); Lucio Martinelli (Paris, FR); Henri Benisty (Palaiseau, FR); Christof Schafauer (Paris, FR); Gabriel Sagarzazu (Ciboure, FR); Thierry Gacoin (Bures sur Yvette, FR); Mélanie Bedu (Toulouse, FR)
Assignee: GEN-PROBE INCORPORATED
G01N21/6428B01L3/502715G01N21/47G01N21/6456G01N21/648G01N21/7703G02B5/00G02B5/02G02B5/0236G02B5/0257G02B6/124G02B6/14G02B6/42G02B6/4206B01L2300/0654B01L2300/0819B01L2300/168G01N21/77G01N2201/0634
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,117,397
App. No.
17/818,637
Filed
Aug 9, 2022
Granted
Oct 15, 2024
Kind
B2
Examiner
TURK, NEIL N
Art Unit
1798
USPC
422/82.08
Abstract

A biochip device includes a waveguide, chromophore elements, a diffusing structure, and a sloping surface. The chromophore elements are disposed on a portion of the waveguide and are configured to emit fluorescence in response to excitation by guided light waves transmitted by the waveguide. The diffusing structure is configured to generate guided light waves in the waveguide when illuminated. The sloping surface is sloped relative to a plane of the waveguide and is configured to direct excitation light into the waveguide, and the sloping surface and the waveguide are configured to deflect the excitation light to the diffusing structure to generate guided light waves within the waveguide. The sloping surface may be a face of a prism attached to or integrated with the waveguide, or the sloping surface may be a bevel formed at an edge of the waveguide.

Claims (26)

1. A biochip device comprising:

a waveguide;

chromophore elements disposed on a portion of the waveguide, wherein the chromophore elements are configured to emit fluorescence in response to excitation by guided light waves transmitted by the waveguide;

a diffusing structure disposed within the waveguide or on the waveguide and configured to generate guided light waves in the waveguide when illuminated; and

a sloping surface of a sloping structure or a sloped end of the waveguide, wherein the sloping surface is sloped relative to a plane of the waveguide and is configured to direct excitation light impinging on the sloping surface into the waveguide and toward the diffusing structure to generate guided light waves within the waveguide, and wherein the diffusing structure is located on a first face of the waveguide and the sloping structures is located on a face of the waveguide other than the first face or the sloped end includes a face of the waveguide other than the first face.

2. The biochip device of claim 1 , wherein the biochip device comprises the sloping structure, the sloping structure is a prism supported on the waveguide, and the sloping surface comprises a face of the prism.

3. The biochip device of claim 2 , further comprising an index-matching layer disposed between the prism and a surface of the waveguide.

4. The biochip device of claim 2 , wherein the prism is integrated with the waveguide.

5. The biochip device of claim 1 , wherein the biochip device comprises the sloped end of the waveguide and the sloping surface of the sloped end of the waveguide is a bevel formed at an edge of the waveguide.

6. The biochip device of claim 1 , wherein the excitation light is parallel to the plane of the waveguide.

7. The biochip device of claim 1 , wherein the excitation light is perpendicular to the plane of the waveguide or is at an angle from the plane of the waveguide inclined relative to perpendicular to the waveguide.

8. The biochip device of claim 1 , wherein the diffusing structure comprises structure having a disordered spatial distribution of refractive index.

9. The biochip device of claim 1 , wherein the diffusing structure comprises one of:

frosting with a grain size of 0.1 μm to 50 μm;

non-uniform metal or dielectric particles,

colloidal particles positioned in the top layer,

micro-cavities formed within the top layer, and

a layer of polytetrafluoroethylene on the top layer.

10. The biochip device of claim 1 , wherein the diffusing structure comprises diffusing particles in a matrix of a resin.

11. The biochip of claim 10 , wherein the matrix is an acrylic resin, a glycerophthalic resin, or a fluoropolymer matrix.

12. The biochip device of claim 10 , wherein the matrix has a refractive index that is less than the refractive index of the diffusing particles.

13. The biochip device of claim 10 , wherein the diffusing particles comprise one of TiO 2 , Ta 2 O 5 , and BaSO 4 .

14. The biochip device of claim 1 , wherein the diffusing structure comprises micro-cavities having dimensions of 0.1 μm to 40 μm.

15. The biochip device of claim 1 , wherein the first face of the waveguide is a face of a top layer and the diffusing structure comprises a layer of fluorophore material that responds to light excitation by generating fluorescent light that propagates in the top layer in the form of waves having an evanescent portion.

16. The biochip device of claim 15 , wherein the fluorophore material comprises quantum dots, organic fluorophores, or fluorophores based on one of rare earth ions and luminescent ions.

17. The biochip device of claim 1 , further comprising an optofluidic portion supported on a surface of the waveguide and comprising a hybridizing chamber containing a hybridizing solution and pads supported on the surface of the waveguide and situated within the hybridizing chamber, wherein the chromophore elements are deposited on the pads.

Assignments (5)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075926/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2024
From: GENEWAVE SAS
To: MOBIBIAG OY
Reel/Frame 068489/0104 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2024
From: MOBIDIAG OY
To: GEN-PROBE INCORPORATED
Reel/Frame 068489/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2022
From: WEISBUCH, CLAUDE; MARTINELLI, LUCIO; BENISTY, HENRI; SCHAFAUER, CHRISTOF; SAGARZAZU, GABRIEL; GACOIN, THIERRY; BEDU, MÉLANIE
To: GENEWAVE
Reel/Frame 061961/0505 →
Priority Claims (1)
FR 1061349 · Dec 29, 2010 · national
Continuity (3)
Continuation 16205256 · Nov 30, 2018
Continuation 13976596
Related Publication 20220381692A1 · Dec 1, 2022